Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage

US11618893B2 · kind B2 · utility

Assignee

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US

Inventors

• Efrat Eliyahu · New York, US
• Adam VINCEK · Gainesville, US
• Anthony Fargnoli · New York, US
• Michael Katz · Regina, CA

Key dates

• Filing date: Sep 11, 2019
• Grant date: Apr 4, 2023
• Expiry date: Feb 12, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y305/01023
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.